Set, Ready, Walk: Gilead Unveils Sovaldi Strategy In China
Executive Summary
Rapid regulatory changes in China are expected to trigger a flurry of new drug launch activities. As Q3 earnings season plays out, Gilead COO Kevin Young talks about doing ‘the right thing’ while rolling out products like the high-priced Sovaldi in China's private-pay market.
You may also be interested in...
PTC Readies China Plan Amid US FDA Translarna Setback
PTC is engaging physicians and Duchenne muscular dystrophy patients in China to access a largely untapped market but regulatory and reimbursement-related uncertainties could pose challenges.
Fosun Kite Bets On Cell Therapy Despite Approval Pathway Lag In China
The approval of Kite's Yescarta has ignited Chinese drug maker Fosun. With a joint venture with Kite in place, the Shanghai conglomerate is looking to accelerate CAR-T development in China despite approval pathway uncertainty.
Deep China Price Cuts Reveal Complex Considerations
Offering deep price discounts in exchange for inclusion in reimbursement lists is never easy, given companies' need to balance expected benefits in volume gains with their international pricing systems and commercial pressures. But in China the underlying considerations are even more complex, as shown by the latest round of national price reductions for selected drugs.